AACR 2021: Humanized CCR8 Mouse Model Provides A Translational Tool For Anti-Human CCR8 Antibody Drug Development
CCR8 plays a critical role in Treg-mediated immunosuppression, indicating CCR8 is a promising target for anti-tumor drug development. Biocytogen generated a humanized B-hCCR8 mouse model…
Read more
AACR 2021: Humanized IL6/hIL6R mouse model supports the evaluation of therapeutic drug candidates targeting human IL6 and IL6 receptor
Interleukin 6 (IL-6) is a pleiotropic cytokine that not only plays an important role in the immune response, but has also been associated with the…
Read more
AACR 2021: Anti-GCGR in vivo efficacy evaluated in a new humanized hGCGR mouse model
Binding of glucagon to its receptor, GCGR, results in an increase in intracellular cAMP levels, which plays a role in promoting glycogenolysis and gluconeogenesis, altogether…
Read more
AACR 2021: Humanized B-hC5AR1 mouse model for evaluation of anti-C5AR1 mAb in vivo efficacy
Activated myeloid-derived suppressor cells upregulate C5AR1 expression, which plays a significant role in inhibiting T cell-related responses. Increased cancer cell invasion and growth by the…
Read more
AACR 2021: Novel Engineered B-NDG B2M KO Mice Plus Shows Delayed GvHD response and Favorable GvL Immune Profiling After hPBMC Engraftment
B-NDG B2M KO mice plus exhibit immunodeficient phenotypes, in which T, B, and NK cells are defective with some histopathological changes in lymphoid organs. B-NDG…
Read more
AACR 2021: Improved LAG-3 humanized knock-in mouse model for assessment of mono- and combination therapy strategies for cancer treatment
LAG-3 is a negative regulator of immunity, such that inhibition of LAG-3 enhances the anti-tumor effect of specific CD8+ T cells. Biocytogen generated a humanized…
Read more
AACR 2021: Double-humanized 4-1BB/4-1BBL mouse is an advanced model for liver toxicity and efficacy evaluation of 4-1BB therapeutic antibodies
4-1BB signaling results in increased cytotoxic T lymphocyte (CTL) activity, cytokine induction, and prevention of activation-induced cell death (AICD). Biocytogen generated a double humanized B-h4-1BB/h4-1BBL…
Read more
AACR 2021: Human CD73 knock-in mice facilitate evaluation of in vivo efficacy of anti-human CD73 cancer immunotherapies
Hypoxia in the tumor microenvironment results in overexpression of CD73, which impairs immune function via adenosine receptors such as A2AR on immune cells. Biocytogen has…
Read more
AACR 2021: Evaluating anti-SIRPα in vivo efficacy in humanized B-NDG hSIRPA mice and B-NDG hSIRPA/hCD47 mice
CD47 binding to SIRPA results in inhibitory signals that protect cancer cells from phagocytosis by macrophages and other myeloid cells. Biocytogen generated humanized SIRPA and…
Read more
AACR 2021: TNFR2 and PD-1/PD-L1/TNFR2 humanized mice aid exploration of combination strategies to overcome tumor immune escape mechanisms
TNF signaling via TNFR2 plays an important role in modulation of the immune system via pro- and anti-inflammatory activities of T cells. Biocytogen has generated…
Read more
AACR 2021: Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo
Beyond its immune regulatory roles, B7-H3 can promote tumor growth, invasion, migration, angiogenesis, and metastasis. To investigate B7-H3 function in vitro and evaluate in vivo…
Read more
AACR 2021: A novel humanized B-hPD-1/hPD-L1/hTIGIT mouse model reveals enhanced efficacy of combined TIGIT and PD-L1 blockade against cancer
Competitive binding of TIGIT to CD155 and CD112 prevents signaling through CD226, which is an NK activating receptor that contributes to anti-tumor responses. Biocytogen established…
Read more